fyv10 Antibody

What is FYV10 and what is its relationship to MAEA?

FYV10 (Function in YPD Vital 10) is a protein initially identified in yeast as a component of the glucose-induced degradation (GID) complex, specifically functioning as a GID complex subunit. In mammalian systems, the homolog is known as MAEA (Macrophage Erythroblast Attacher) or GID9, which functions as an E3 ubiquitin-protein transferase . FYV10/MAEA is involved in multiple cellular processes including negative regulation of gluconeogenesis, cell proliferation, and erythroblast-macrophage interactions. The protein has several alternative designations including Cell proliferation-inducing gene 5 protein (PIG5), Erythroblast macrophage protein (EMP), and Human lung cancer oncogene 10 protein (HLC-10) .

What experimental techniques are most effective for detecting FYV10 in research specimens?

Multiple experimental approaches can effectively detect FYV10/MAEA in research specimens, with selection depending on experimental goals and sample characteristics. Western blotting offers quantitative protein expression analysis and size verification, while immunohistochemistry (IHC) provides spatial localization data in tissue sections . For cellular localization studies, immunofluorescence and immunocytochemistry provide high-resolution imaging capabilities . ELISA techniques allow for quantitative measurement in solution-based samples . When designing experiments, consider using multiple detection methods for cross-validation of results, particularly when characterizing new antibodies or investigating novel expression patterns.

How should researchers validate the specificity of FYV10 antibodies?

Validation of FYV10 antibody specificity requires a multi-faceted approach. Begin with positive and negative control samples—tissues or cell lines with known high or absent expression of FYV10. For definitive validation, perform experiments with genetic knockdown/knockout models where FYV10 expression is reduced or eliminated . Western blot analysis should demonstrate a single band at the expected molecular weight (approximately 44 kDa for human MAEA). Preabsorption tests with the immunizing peptide can further confirm specificity by blocking antibody binding. For polyclonal antibodies, which are common for FYV10 detection based on the search results, batch-to-batch variation necessitates consistent validation protocols across different lots to ensure reproducible experimental outcomes.

How does FYV10's role in the glucose-induced degradation complex contribute to metabolic regulation?

FYV10/GID9 functions as a core component of the glucose-induced degradation (GID) complex, which plays a crucial role in the negative regulation of gluconeogenesis. In yeast systems, where this function has been best characterized, the GID complex targets key gluconeogenic enzymes for ubiquitination and subsequent proteasomal degradation during the transition from gluconeogenic to glycolytic growth conditions. The complex recognizes specific degrons in target proteins and facilitates their polyubiquitination, effectively shutting down gluconeogenesis when glucose becomes available. In mammalian systems, MAEA (the FYV10 homolog) maintains this E3 ubiquitin ligase activity as part of the CTLH complex, though with expanded substrate specificity beyond metabolic enzymes. This evolutionarily conserved role makes FYV10/MAEA a potential target for research into metabolic disorders and cancer metabolism, where altered gluconeogenesis regulation often occurs.

What is the relationship between FYV10/MAEA expression and cancer progression?

The designation of MAEA as Human lung cancer oncogene 10 protein (HLC-10) suggests important implications in cancer biology . Research indicates MAEA may function as both a tumor suppressor and oncogene depending on cellular context and cancer type. Its E3 ubiquitin ligase activity regulates protein turnover for multiple substrates involved in cell cycle control, potentially explaining its dual nature in cancer progression. Altered MAEA expression has been associated with cellular proliferation changes, as indicated by its alternative name "Cell proliferation-inducing gene 5 protein" . For researchers investigating MAEA in cancer contexts, examining its expression in correlation with cellular proliferation markers, ubiquitination patterns of known substrates, and interaction with other GID complex components provides mechanistic insights into its role in tumor development and progression.

How does FYV10/MAEA contribute to erythroblast-macrophage interactions in hematopoiesis?

MAEA plays a crucial role in erythropoiesis as a mediator of erythroblast-macrophage interactions within erythroblastic islands . These specialized niches in bone marrow support erythrocyte development through direct cell-cell contacts. MAEA functions as an attachment factor expressed on both macrophages and developing erythroblasts, facilitating adhesion between these cell types and supporting the terminal stages of erythrocyte maturation. Researchers investigating this process should consider co-immunoprecipitation experiments to identify MAEA interaction partners in erythroid cells and macrophages. Time-course analyses during erythroid differentiation can reveal dynamic changes in MAEA expression and localization. For comprehensive understanding, combining antibody-based detection with genetic approaches (conditional knockout models) would provide insights into the temporal requirements for MAEA during different stages of erythropoiesis.

What are the optimal fixation and retrieval methods for immunohistochemical detection of FYV10?

For immunohistochemical detection of FYV10/MAEA, optimization of fixation and antigen retrieval protocols is essential for maintaining both tissue morphology and epitope accessibility. Paraformaldehyde fixation (4%) for 24-48 hours provides good preservation of tissue architecture while retaining FYV10 antigenicity . For paraffin-embedded sections, heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is generally effective, with optimal conditions requiring empirical determination for specific antibodies. When using commercially available antibodies, adherence to manufacturer recommendations is advisable as a starting point, with subsequent optimization based on signal-to-noise ratio in control tissues. For dual-labeling experiments involving FYV10 and its interaction partners, sequential staining protocols may be necessary to avoid cross-reactivity between detection systems.

How can researchers troubleshoot weak signal issues in FYV10 Western blot experiments?

When encountering weak signal issues in FYV10 Western blot experiments, a systematic troubleshooting approach is recommended. First, verify protein extraction efficiency by examining total protein content using reversible stains before transfer. FYV10/MAEA may require specialized extraction buffers containing appropriate detergents (e.g., RIPA buffer with protease inhibitors) to ensure complete solubilization . For detection, consider extending primary antibody incubation time (overnight at 4°C) and optimizing antibody concentration through titration experiments. Signal amplification systems such as biotin-streptavidin can enhance detection sensitivity for low-abundance targets. If protein degradation is suspected, include additional protease inhibitors in extraction buffers and maintain samples at cold temperatures throughout processing. For particularly challenging samples, membrane stripping and reprobing with alternative FYV10 antibodies recognizing different epitopes may help determine whether the issue relates to antibody specificity or protein abundance.

What approaches can be used to study FYV10 protein-protein interactions?

Investigation of FYV10/MAEA protein-protein interactions requires multiple complementary approaches. Co-immunoprecipitation using FYV10 antibodies followed by mass spectrometry analysis provides an unbiased screen for interaction partners . For targeted analysis of suspected interactions, reciprocal co-immunoprecipitation experiments with antibodies against both FYV10 and the protein of interest offer confirmatory evidence. Proximity ligation assays provide spatial information about interactions within intact cells, while bimolecular fluorescence complementation allows visualization of interactions in living cells. For mapping interaction domains, researchers should consider pull-down assays with recombinant protein fragments. When studying interactions within the GID complex specifically, tandem affinity purification followed by mass spectrometry can reveal the complete interactome under different metabolic conditions.

What controls should be included when using FYV10 antibodies for immunoprecipitation studies?

Robust immunoprecipitation studies using FYV10 antibodies require comprehensive controls to ensure result validity. Include an isotype control antibody (matching the host species and isotype of the FYV10 antibody) to identify non-specific binding . Implement a no-antibody control to assess background binding to the precipitation matrix (protein A/G beads). For definitive validation, include a negative control sample where FYV10 expression has been knocked down via RNA interference or CRISPR-Cas9 genome editing. If analyzing a specific FYV10 interaction, competition assays with excess recombinant FYV10 protein can confirm binding specificity. When studying post-translational modifications, appropriate inhibitors or activators of the relevant modifying enzymes should be included as experimental conditions to demonstrate dynamic regulation of FYV10 modification states.

How should researchers quantify changes in FYV10 expression levels across experimental conditions?

Accurate quantification of FYV10 expression changes requires careful normalization and statistical analysis. For Western blot quantification, normalize FYV10 band intensity to multiple housekeeping proteins (e.g., GAPDH, β-actin, and tubulin) to control for loading variations . Digital image analysis using software with dynamic range verification prevents quantification artifacts from saturated signals. For immunohistochemical quantification, consider both staining intensity and percentage of positive cells using standardized scoring systems. Flow cytometry provides single-cell resolution for expression level distribution within populations. qRT-PCR analysis of FYV10 mRNA levels should complement protein expression data to distinguish between transcriptional and post-transcriptional regulation mechanisms. Statistical analysis should employ appropriate tests based on data distribution, with multiple biological replicates (minimum n=3) to ensure reproducibility.

How do post-translational modifications affect FYV10 function in different cellular contexts?

FYV10/MAEA undergoes multiple post-translational modifications that regulate its function, localization, and protein interactions. As an E3 ubiquitin ligase component, FYV10 itself is subject to ubiquitination, which may regulate its stability and activity through autoregulatory mechanisms. Phosphorylation at multiple residues occurs in response to changing metabolic conditions, potentially affecting substrate recognition or complex assembly. To study these modifications, researchers should combine immunoprecipitation with phospho-specific antibodies or mass spectrometry analysis. Pharmacological inhibitors of specific kinases or phosphatases can help identify regulatory pathways. For ubiquitination studies, proteasome inhibitors (e.g., MG132) reveal modification patterns that would otherwise be rapidly degraded. Site-directed mutagenesis of key modification sites followed by functional assays provides direct evidence for the importance of specific modifications in FYV10 activity regulation.

What are the optimal protein extraction protocols for preserving FYV10 integrity and interactions?

Preserving FYV10 integrity and protein-protein interactions during extraction requires careful buffer selection and handling procedures. For maintaining native protein complexes, gentle non-ionic detergents (0.5-1% NP-40 or 1% digitonin) in physiological buffers (150mM NaCl, 50mM Tris-HCl, pH 7.4) are recommended . Include protease inhibitor cocktails, phosphatase inhibitors, and deubiquitinase inhibitors (N-ethylmaleimide) to preserve post-translational modifications. Perform all extraction steps at 4°C to minimize protein degradation. For nuclear and cytoplasmic fractionation studies, commercial kits or differential centrifugation protocols can separate these compartments while maintaining protein integrity. When studying membrane-associated pools of FYV10, consider sequential extraction with increasingly stringent buffers to distinguish between peripheral and integral membrane associations. Verification of extraction efficiency should include Western blot analysis of compartment-specific markers to confirm successful fractionation.